Products SEO & GEO Agent Paid Ads Agent Website Agent Conversion Agent
How it works Pricing FAQ Blog Book a call

MedTech content: clear, compliant pages for complex devices

Updated · 7 min read

Short answer Write every page inside your cleared or licensed claim. Say "FDA cleared" for a 510(k) device, never "approved"; don't promote uses outside your indications or a device still under study; and in Canada, don't advertise a Class II to IV device before it has a licence. Then layer the same claim for patients, clinicians and buyers.

Want help applying this to your business? Talk it through on a free 30-minute call.

Book a call

The rule: write inside your cleared claim

A device company's website, blog, emails and videos all count as evidence of what the device is for. FDA's rule on intended use says that intent "may, for example, be shown by labeling claims, advertising matter, or oral or written statements" (21 CFR 801.4). So a blog post that hints at a new use can make a cleared device look like it is being sold for something FDA never reviewed.

Start every piece from the exact wording FDA cleared or approved (your indications for use) or Health Canada licensed. These are the lines content most often crosses:

What the content saysRuleSay instead
"FDA approved" for a 510(k) deviceClearance "does not in any way denote official approval" (21 CFR 807.97)"FDA cleared" with the 510(k) number
"FDA registered" as a selling pointImplying approval from registration is misbranding (21 CFR 807.39)Leave it out
A use beyond your indicationsYour own words can show a new intended use (21 CFR 801.4)The cleared use only; off-label science goes on a separate page for clinicians (below)
"Safe and effective" about a device still in a clinical studyBanned for investigational devices (21 CFR 812.7)Describe the study, not the result you hope for
A patient story as proof it worksTestimonials need the same proof as your own claim (16 CFR 255.2)Pair the story with what patients generally experience
Canada: an ad for a Class II to IV device without a licenceNot allowed, except in a catalogue with a warning (Medical Devices Regulations, s. 27)Wait for the licence

FDA itself explains the difference in plain terms: the highest-risk devices get "approval" of a premarket application, moderate-risk devices get "510(k) clearance," and "Mere registration of an establishment or listing of a drug or device does not denote approval" (FDA: Is It Really 'FDA Approved'?).

This is what the rules say, not legal advice. Your regulatory lead or counsel decides how they apply to your device.

Who regulates medical device marketing?

It depends on the device and the country.

  • US, labeling: FDA, for every device. A device is misbranded "If its labeling is false or misleading in any particular" (21 U.S.C. 352(a)).
  • US, advertising of restricted devices: FDA. A restricted device is misbranded if "its advertising is false or misleading in any particular," and its ads must carry a brief statement of intended uses, warnings, precautions, side effects and contraindications (21 U.S.C. 352(q) and (r)).
  • US, other device advertising: the FTC, under its truth-in-advertising law. FTC guidance notes that it and FDA "share jurisdiction over the marketing of dietary supplements, foods, drugs, devices, and other health-related products" (FTC Health Products Compliance Guidance).
  • Canada: Health Canada, under the Food and Drugs Act. No one may advertise a device "in a manner that is false, misleading or deceptive" about its "performance, intended use" or safety, among other things (Food and Drugs Act, s. 20). Performance claims also need "an adequate and proper test," with the proof on you (Competition Act, s. 74.01).

The proof bar is high in the US too. For health benefits, the FTC says substantiation generally "will need to be in the form of randomized, controlled human clinical testing" (FTC Health Products Compliance Guidance). And patient stories don't count on their own:

"Consumer endorsements themselves are not competent and reliable scientific evidence." (16 CFR 255.2(a))

How to explain a complex device in plain words

Keep one approved claim and write it at three depths. The facts stay the same; the detail and words change.

ReaderWhat they need firstFormat that fits
Patient or caregiverWhat it does, what it feels like, what can go wrongShort page, steps, a 2-minute video
ClinicianIndications, technique, study data, contraindicationsClinical summary, procedure video, data sheet
Hospital buyer or ITCost, fit with current equipment and systems, trainingSpec sheet, integration notes, a cost worksheet built on their numbers

For patient pages, FDA's own patient labeling guidance gives a usable target: the text "should be no higher than the eighth-grade level, the average reading level among adults" (FDA Guidance on Medical Device Patient Labeling, 2001). The same guidance asks writers to assume the user has no device or medical knowledge and to give steps in order. It is written for labeling, but it works for any patient-facing page.

What makes device writing readable:

  • One idea per sentence. Put the benefit first, then how it works.
  • Define each term once. "Stent (a small mesh tube that holds an artery open)."
  • Show, don't describe. A labeled diagram or a short clip of the device in use replaces a paragraph of specs.
  • Risks in the same voice as benefits. Hiding them in small print reads as spin, and for restricted devices the risk statement is required (21 U.S.C. 352(r)).
  • Name who wrote and reviewed it. A clinician reviewer's name and date shows the expertise search engines and readers look for (E-E-A-T).

Off-label data and pre-launch content

Off-label science for clinicians. FDA's January 2025 guidance lets firms share some scientific information about unapproved uses with health care providers, but keeps it apart from sales content. On websites, FDA "recommends that SIUU communications be on a separate web page from the web page that hosts promotional communications" and that firms "not include direct links" from product pages to it (FDA guidance, January 2025). So: no off-label study on the product page, no link from it, and the required disclosures on the separate page.

Before clearance (US). A sponsor may not "promote or test market an investigational device" until FDA allows it to be sold (21 CFR 812.7). Content about the problem you solve, your team and your study design is a different thing from selling the device. Your regulatory lead draws that line.

Before a licence (Canada). Class II, III and IV devices can't be advertised for sale until the manufacturer holds a licence, unless the ad is only in a catalogue with a clear warning that the devices "may not have been licensed in accordance with Canadian law" (Medical Devices Regulations, s. 27).

A review process that doesn't stall publishing

Most delays come from reviewing every sentence from scratch. A claims library fixes that.

  1. Build a claims library. Each approved claim, its exact wording, the evidence behind it, and the countries where it may be used.
  2. Write from the library. Writers (or AI drafting tools) may only use approved claims. Google cares whether content is helpful, not whether AI wrote it (AI content and Google), but every AI draft still goes through review.
  3. Route by risk. A post that reuses library claims gets a light check. A new claim, a comparison with a competitor, a patient story or anything for clinicians gets full medical, legal and regulatory review.
  4. Measure by reader. Patient pages: time on page and questions to support. Clinician pages: data sheet downloads and demo requests. Buyer pages: quote requests. Cut or fix what no one uses.
  5. Date every page and recheck it when your indications, labeling or data change. Stale pages are a compliance risk, not just an SEO one (update old pages).

On privacy: Europe's GDPR can apply when you handle data from people in the EU, and California's CCPA applies only to businesses above set thresholds, such as gross annual revenue of $26.625 million or more, or buying, selling or sharing the personal information of 100,000 or more California residents or households (California Privacy Protection Agency). Check which apply before you copy someone else's privacy setup.

Example

Illustrative cases. Figures in US dollars.

A 510(k)-cleared wearable monitor

Its homepage said "FDA approved." The team changes it to "FDA cleared" with the 510(k) number, adds a patient page written at an eighth-grade level, and moves a study on an unapproved use to a separate clinician page with no link from the product page.

A startup still in its pivotal trial

It wants traffic before launch. It publishes articles on the condition, its team and how the trial works, and states no safety or effectiveness results. Its first product page goes live after FDA authorization.

A Canadian distributor of a Class II device

Its US partner's site advertises the device, but the Canadian licence is pending. The Canadian site lists the device only in a catalogue that carries the section 27 warning until the licence arrives.

FAQ

Can a medical device company publish patient testimonials?

Yes, within your cleared use. It needs the same proof as your own claim, and if it isn't typical, disclose what patients generally experience (16 CFR 255.2).

Is a blog post labeling or advertising?

It can be either, depending on how it relates to the device. Either way, FDA can read it as evidence of your intended use (21 CFR 801.4).

Can we say "FDA approved" for a Class I exempt device?

No. Most Class I devices go to market without any FDA premarket review, so there is no approval or clearance to claim (FDA).

Do US rules cover our Canadian website?

No. Canada applies the Food and Drugs Act, Medical Devices Regulations and Competition Act. A US clearance doesn't license a device in Canada.

Different for you?

Keep learning

NextB2B tech SEO: winning search when deals take monthsB2B tech SEO for long sales cycles: find low-volume buyer keywords, track organic leads to closed deals, and earn links without breaking Google's rules.

Ask us one question

One line is enough. We reply by email.

Sources

  1. 21 CFR 807.97, Misbranding by reference to premarket notification (eCFR)
  2. 21 CFR 807.39, Misbranding by reference to establishment registration (eCFR)
  3. 21 CFR 801.4, Meaning of intended uses (eCFR)
  4. 21 CFR 812.7, Prohibition of promotion and other practices (eCFR)
  5. 21 U.S.C. 352, misbranded drugs and devices (Cornell LII)
  6. FDA: Is It Really 'FDA Approved'?
  7. FDA: Communications From Firms to Health Care Providers Regarding Scientific Information on Unapproved Uses of Approved/Cleared Medical Products (January 2025)
  8. FDA: Guidance on Medical Device Patient Labeling (April 19, 2001)
  9. FTC: Health Products Compliance Guidance
  10. 16 CFR 255.2, FTC Endorsement Guides: Consumer endorsements (eCFR)
  11. Medical Devices Regulations (SOR/98-282), section 27 (Justice Laws)
  12. Food and Drugs Act, section 20 (Justice Laws)
  13. Competition Act, section 74.01 (Justice Laws)
  14. California Privacy Protection Agency: FAQ